Skip to main content
Equibles
MYGN logo

MYGN · Myriad Genetics Inc · Webcasts, Transcripts & Audio

Track MYGN — free

Use MYGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MYGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.58 -0.06 (-0.83%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$634.16M
Shares
95.65M
Volume · Oct 29 328.1K Avg daily vol (3M) 2.63M

Myriad Genetics Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Myriad Genetics Inc (MYGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Myriad Genetics Inc (MYGN) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-10
Myriad Genetics Inc (MYGN) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Myriad Genetics Inc (MYGN) Q2 2026 Earnings Call Transcript
Cautious tone Hereditary Cancer (MyRisk) reimbursement pressure Precise MRD launch and milestones Hereditary Cancer Testing (MyRisk) volume growth
Revenue
$190.70M
▼ 10.5% YoY
Diluted EPS
$-0.46
Gross margin
66.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Myriad Genetics Inc (MYGN) Q1 2026 Earnings Call Transcript
Positive tone Cancer Care Continuum strategy Prenatal business decline and FirstGene launch Commercial team expansion
Revenue
$200.40M
▲ 2.3% YoY
Diluted EPS
$-0.36
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Transcript
Positive tone Precise MRD launch Prenatal health MyRisk hereditary cancer testing
Revenue
$209.80M*
▼ 0.4% YoY
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Myriad Genetics Inc (MYGN) Q3 2025 Earnings Call Transcript
Positive tone MyRisk hereditary cancer test growth Financial results and guidance GeneSight and UnitedHealthcare headwind
Revenue
$205.70M
▼ 3.6% YoY
Diluted EPS
$-0.29
Gross margin
69.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Myriad Genetics Inc (MYGN) Q2 2025 Earnings Call Transcript
Confident tone Prenatal business disruption Hereditary cancer testing (MyRisk) Pricing and revenue cycle improvement
Revenue
$213.10M
▲ 0.8% YoY
Diluted EPS
$-3.57
Gross margin
71.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Transcript
Cautious tone GeneSight and UnitedHealthcare headwind Unaffected hereditary cancer and EMR integration Prolaris and NCCN positioning
Revenue
$195.90M
▼ 3.1% YoY
Diluted EPS
$0.00
Gross margin
68.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-15
Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Transcript
Positive tone Oncology strategy and continuum of care PATHOMIQ partnership and AI Product launches and pipeline
Revenue
$210.60M*
▲ 7.1% YoY
Gross margin
71.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-09
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Transcript
Positive tone GeneSight and UnitedHealthcare policy change Oncology and MRD opportunity Hereditary Cancer testing (MyRisk and BRACAnalysis CDx)
Revenue
$213.30M
▲ 11.2% YoY
Diluted EPS
$-0.24
Gross margin
70.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Myriad Genetics Inc (MYGN) Q2 2024 Earnings Call Transcript
Confident tone Prenatal / Women's Health GeneSight and pharmacogenomics Hereditary cancer testing (MyRisk / BRACAnalysis CDx)
Revenue
$211.50M
▲ 15.3% YoY
Diluted EPS
$-0.41
Gross margin
69.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Myriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript
Confident tone Oncology portfolio / Precise Tumor and Liquid GeneSight FDA final rule on lab-developed tests
Revenue
$202.20M
▲ 11.6% YoY
Diluted EPS
$-0.29
Gross margin
68.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-16
Myriad Genetics Inc (MYGN) Q4 2023 Earnings Call Transcript
Confident tone GeneSight pharmacogenomics Women's health and hereditary cancer ASP and reimbursement outlook
Revenue
$196.60M*
▲ 10.6% YoY
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Myriad Genetics Inc (MYGN) Q3 2023 Earnings Call Transcript
Revenue
$191.90M
▲ 22.7% YoY
Diluted EPS
$-0.75
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Myriad Genetics Inc (MYGN) Q2 2023 Earnings Call Transcript
Revenue
$183.50M
▲ 2.3% YoY
Diluted EPS
$-1.42
Gross margin
68.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Myriad Genetics Inc (MYGN) Q1 2023 Earnings Call Transcript
Revenue
$181.20M
▲ 9.9% YoY
Diluted EPS
$-0.67
Gross margin
67.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Myriad Genetics Inc (MYGN) Q4 2022 Earnings Call Transcript
Revenue
$177.80M*
▲ 10.6% YoY
Gross margin
69.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Myriad Genetics Inc (MYGN) Q3 2022 Earnings Call Transcript
Revenue
$156.40M
▼ 6.5% YoY
Diluted EPS
$-0.43
▼ 243.3% YoY
Gross margin
67.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Myriad Genetics Inc (MYGN) Q2 2022 Earnings Call Transcript
Revenue
$179.30M
▼ 5.3% YoY
Diluted EPS
$-0.18
Gross margin
72.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Myriad Genetics Inc (MYGN) Q1 2022 Earnings Call Transcript
Revenue
$164.90M
▼ 4.7% YoY
Diluted EPS
$-0.26
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Myriad Genetics Inc (MYGN) Q4 2021 Earnings Call Transcript
Revenue
$160.80M*
▲ 4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Myriad Genetics Inc (MYGN) Q3 2021 Earnings Call Transcript
Revenue
$167.30M
▲ 2% YoY
Diluted EPS
$0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Myriad Genetics Inc (MYGN) Q2 2021 Earnings Call Transcript
Revenue
$189.40M
▼ 2.9% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Myriad Genetics Inc (MYGN) Q4 2020 Earnings Call Transcript
Revenue
$154.60M
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Myriad Genetics Inc (MYGN) Q3 2020 Earnings Call Transcript
Revenue
$164.00M
Diluted EPS
$-1.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Myriad Genetics Inc (MYGN) Q2 2020 Earnings Call Transcript
Revenue
$195.10M
▼ 9.4% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Myriad Genetics Inc (MYGN) Q1 2020 Earnings Call Transcript
Revenue
$186.30M
▼ 14% YoY
Diluted EPS
$-0.28
▼ 411.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Myriad Genetics Inc (MYGN) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 899923 CUSIP 62855J104 13F (30d) 25 filings 25 filers Visit website Investor relations